SG Americas Securities LLC lowered its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating) by 43.4% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 29,966 shares of the company’s stock after selling 23,023 shares during the quarter. SG Americas Securities LLC’s holdings in Myriad Genetics were worth $572,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of MYGN. First Horizon Advisors Inc. acquired a new position in shares of Myriad Genetics in the 2nd quarter valued at about $57,000. Point72 Hong Kong Ltd lifted its holdings in shares of Myriad Genetics by 722.8% in the 2nd quarter. Point72 Hong Kong Ltd now owns 3,217 shares of the company’s stock valued at $58,000 after buying an additional 2,826 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of Myriad Genetics by 216.7% in the 2nd quarter. Exchange Traded Concepts LLC now owns 3,588 shares of the company’s stock valued at $65,000 after buying an additional 2,455 shares during the period. Ronald Blue Trust Inc. lifted its holdings in shares of Myriad Genetics by 21.2% in the 3rd quarter. Ronald Blue Trust Inc. now owns 4,439 shares of the company’s stock valued at $81,000 after buying an additional 775 shares during the period. Finally, CWM LLC lifted its holdings in shares of Myriad Genetics by 17.8% in the 3rd quarter. CWM LLC now owns 4,291 shares of the company’s stock valued at $82,000 after buying an additional 648 shares during the period. Institutional investors and hedge funds own 99.08% of the company’s stock.
Myriad Genetics Trading Up 5.2 %
NASDAQ:MYGN opened at $21.41 on Tuesday. Myriad Genetics, Inc. has a 12 month low of $13.92 and a 12 month high of $28.18. The stock has a 50 day moving average of $18.04 and a two-hundred day moving average of $20.49. The firm has a market cap of $1.73 billion, a P/E ratio of -22.07 and a beta of 1.75.
Wall Street Analysts Forecast Growth
MYGN has been the subject of several analyst reports. StockNews.com initiated coverage on Myriad Genetics in a report on Wednesday, October 12th. They issued a “hold” rating for the company. Raymond James upgraded Myriad Genetics from a “market perform” rating to an “outperform” rating and set a $25.00 price target for the company in a research note on Wednesday, January 18th. SVB Leerink cut their price target on Myriad Genetics from $27.00 to $25.00 and set a “market perform” rating for the company in a research note on Wednesday, November 2nd. Finally, Stephens began coverage on Myriad Genetics in a research note on Wednesday, October 5th. They issued an “equal weight” rating and a $22.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $25.40.
Insiders Place Their Bets
In other Myriad Genetics news, CFO Richard Bryan Riggsbee sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 27th. The stock was sold at an average price of $15.15, for a total transaction of $303,000.00. Following the completion of the sale, the chief financial officer now directly owns 374,107 shares in the company, valued at approximately $5,667,721.05. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders sold 30,000 shares of company stock worth $503,382. Corporate insiders own 1.80% of the company’s stock.
Myriad Genetics Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
- Get a free copy of the StockNews.com research report on Myriad Genetics (MYGN)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.